PONCE, RAFAEL A., JR.,BROLY, HERVE,GRAFFNER, HANS OTTO LENNART,PEANO, SERGIO
申请号：
CA2701329
公开号：
CA2701329C
申请日:
2008.10.16
申请国别(地区):
CA
年份:
2017
代理人:
摘要：
The invention relates to novel combination therapies involving BLyS orBLyS/APRIL inhibition and anti-CD20agents for the treatment of autoimmune diseases. One preferred method is wherethe BLyS antagonist is a Fc-fusion protein whichcan be a TACI-Fc-fusion protein comprising the extracellular domain of TACI ora functional fragment thereof, a BAFF-R-Fc-fusionprotein comprising the extracellular domain of BAFF-R or a functional fragmentthereof, or a BCMA-Fc-fusion protein comprisingthe extracellular domain of BCMA or a functional fragment thereof. In themethods of the present invention some of anti-CD20agents contemplated include RITUXAN®, ocrelizumab, ofatumumab (HuMax-CD20®), TRU-015, and DXL625, although any agentthat binds to CD 20 may be suitable. The methods of the present inventionreduce the levels of B cells in patients in need of suchreduction, such as those suffering from autoimmune diseases.
